Literature DB >> 23470321

Molecular mechanisms of T cell co-stimulation and co-inhibition.

Lieping Chen1, Dallas B Flies.   

Abstract

Co-stimulatory and co-inhibitory receptors have a pivotal role in T cell biology, as they determine the functional outcome of T cell receptor (TCR) signalling. The classic definition of T cell co-stimulation continues to evolve through the identification of new co-stimulatory and co-inhibitory receptors, the biochemical characterization of their downstream signalling events and the delineation of their immunological functions. Notably, it has been recently appreciated that co-stimulatory and co-inhibitory receptors display great diversity in expression, structure and function, and that their functions are largely context dependent. Here, we focus on some of these emerging concepts and review the mechanisms through which T cell activation, differentiation and function is controlled by co-stimulatory and co-inhibitory receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23470321      PMCID: PMC3786574          DOI: 10.1038/nri3405

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  134 in total

1.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

2.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

Review 3.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

Review 4.  Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer.

Authors:  Christopher J Chan; Daniel M Andrews; Mark J Smyth
Journal:  Curr Opin Immunol       Date:  2012-01-28       Impact factor: 7.486

5.  Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.

Authors:  Jill M Angelosanto; Shawn D Blackburn; Alison Crawford; E John Wherry
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

6.  Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.

Authors:  Yukimi Sakoda; Jang-June Park; Yuming Zhao; Atsuo Kuramasu; Degui Geng; Yingjia Liu; Eduardo Davila; Koji Tamada
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

Review 7.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

8.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.

Authors:  John R Sedy; Maya Gavrieli; Karen G Potter; Michelle A Hurchla; R Coleman Lindsley; Kai Hildner; Stefanie Scheu; Klaus Pfeffer; Carl F Ware; Theresa L Murphy; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2004-11-28       Impact factor: 25.606

Review 9.  Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Authors:  Chao Wang; Gloria H Y Lin; Ann J McPherson; Tania H Watts
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Authors:  Lukas Baitsch; Amandine Legat; Leticia Barba; Silvia A Fuertes Marraco; Jean-Paul Rivals; Petra Baumgaertner; Céline Christiansen-Jucht; Hanifa Bouzourene; Donata Rimoldi; Hanspeter Pircher; Nathalie Rufer; Maurice Matter; Olivier Michielin; Daniel E Speiser
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

View more
  1016 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Programmed cell death-1 single-nucleotide polymorphism rs10204525 is associated with human immunodeficiency virus type 1 RNA viral load in HIV-1-infected Moroccan subjects.

Authors:  Hanâ Baba; Anass Kettani; Meryem Bouqdayr; Ahd Ouladlahsen; Rajaa Bensghir; Latifa Marih; Mustapha Sodqi; Soumaya Benjelloun; Sayeh Ezzikouri; Imane Zaidane; Fatima-Zahra Jadid; Kamal Marhoum El Filali; Lahcen Wakrim
Journal:  Med Microbiol Immunol       Date:  2021-05-24       Impact factor: 3.402

3.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 4.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

Review 6.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

7.  Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.

Authors:  A Picchianti Diamanti; M M Rosado; M Scarsella; V Germano; E Giorda; S Cascioli; B Laganà; R D'Amelio; R Carsetti
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

8.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

Review 9.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

10.  Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

Authors:  Qian Zhang; Hong Yi Wang; Fang Wei; Xiaobin Liu; Jennifer C Paterson; Darshan Roy; Daniela Mihova; Anders Woetmann; Andrzej Ptasznik; Niels Odum; Stephen J Schuster; Teresa Marafioti; James L Riley; Mariusz A Wasik
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.